Combination of TURP and Standard Systemic Therapy for MPCa

Prior treatment

• History of seizures or medications known to lower the seizure threshold, or any disease that may induce seizures (e.g., stroke or transient ischemic attacks) within 12 months prior to the study.
• Recent Major Surgery: Patients who have undergone major surgery within 4 weeks before starting the study treatment.
• Patients currently receiving any investigational drugs or devices.

Other illness

• History of hypersensitivity or intolerance to any of the drugs used in the study.
• Patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who have already undergone TURP and do not present with lower urinary tract obstruction or hematuria.
• Oligometastatic mHSPC Patients: Patients with oligometastatic hormone-sensitive prostate cancer (mHSPC) who are planning to undergo radical prostatectomy as the primary treatment.
• History of severe or unstable cardiovascular disease within the last 6 months, including severe angina, myocardial infarction, congestive heart failure (NYHA III or higher), cerebrovascular accident, or requiring medication for arrhythmia.
• Severe Digestive Disorders: Patients with chronic diarrhea, bowel obstruction, or other factors affecting drug absorption.
• Patients with active infections, including HIV, hepatitis B (HBsAg-positive), or hepatitis C, that may affect the safety and efficacy of the treatment.
• Patients diagnosed with other malignancies in the past 3 years, excluding cured basal cell carcinoma of the skin.
• Patients with active brain metastases or leptomeningeal disease.
• Any condition that the investigator believes could compromise the patient's safety or interfere with the study results (e.g., uncontrolled hypertension, severe diabetes, psychiatric conditions).

Other

• Patients with significant contraindications to TURP, such as severe urethral stricture or inability to catheterize.
• Patients who are unlikely to comply with the treatment protocol and follow-up schedule.

• Patients must voluntarily agree to participate and provide signed informed consent.
• aged 18 to 80 years.
• Pathologically or cytologically confirmed adenocarcinoma of the prostate, with neuroendocrine differentiation components ≤10%, and no small cell or signet ring cell carcinoma histological features.
• Newly diagnosed metastatic prostate cancer with evidence of metastasis (lymph node, bone, or visceral metastases) confirmed by PSMA/PET-CT, CT, or MRI.
• Patients must not have participated in or plan to participate in another clinical trial.
• ECOG PS score of 0-1.
• Adequate Organ and Bone Marrow Function:
  • Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L (1500/μL).
  • Hemoglobin ≥ 90 g/L (9.0 g/dL).
  • Platelet count ≥ 80×10⁹/L (100,000/μL).
  • Liver function: total bilirubin ≤ 1.5×ULN, AST/ALT and alkaline phosphatase ≤ 2.5×ULN.
  • Ⅴ. Kidney function: serum creatinine ≤ 2×ULN or calculated creatinine clearance ≥ 30 mL/min.
  • Ⅵ. Coagulation function: INR ≤ 1.5.